FDA Grants Priority Review to Belantamab Mafodotin for Heavily-treated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted priority…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Darzalex Combo Approved in Europe to Treat Transplant-eligible Myeloma Patients
The European Commission has approved Darzalex…
NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients
NexImmune will soon initiate a Phase 1/2 trial…
IMF, Medscape Oncology Offer Medical Education Series on Continuous Treatment in Myeloma
In partnership with Medscape Oncology, the International…
First Mainland China Patient Dosed in Pivotal Phase 2 Trial Testing MOR202 in Multiple Myeloma
I-Mab Biopharma has dosed the first patient in…
Pivotal DREAMM-2 Trial Supports Belantamab Mafodotin’s Use for Heavily-treated Multiple Myeloma
Treatment with belantamab mafodotin, GlaxoSmithKline’s…
